Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday reported positive high-level results from the Phase III MIRANDA trial, demonstrating that its IL-33-targeting biologic, tozorakimab, achieved a statistically significant and clinically meaningful reduction in the annualised rate of moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD).

The trial met its primary endpoint in former smokers and also showed efficacy across the broader population, including current smokers and patients spanning all blood eosinophil counts and lung function severity. Patients received tozorakimab 300mg or placebo every two weeks in addition to standard inhaled therapy.

These results mark the third successful pivotal Phase III outcome for tozorakimab, following positive data from the OBERON and TITANIA trials announced in March 2026. The therapy was generally well tolerated, with a safety profile consistent with earlier studies. AstraZeneca PLC confirmed that the data will be submitted to regulatory authorities and presented at an upcoming medical meeting.

Tozorakimab is a potential first-in-class monoclonal antibody targeting interleukin-33 (IL-33), designed to reduce inflammation and disrupt mucus dysfunction associated with COPD progression. The drug is also under investigation in a Phase III trial for severe viral lower respiratory tract disease and a Phase II trial in asthma.

COPD remains a leading global health challenge, affecting nearly 400 million people and ranking as the third leading cause of death worldwide. AstraZeneca continues to position respiratory and immunology as a core growth area, advancing a pipeline of biologics and inhaled therapies aimed at addressing unmet needs in chronic respiratory diseases.